Paulina Lau

Paulina Lau

Auto-generated profile, based on publicly available information

Paulina Lau

Atherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
SSSebastien Soubeyrand
Sebastien Soubeyrand
PLPaulina Lau
Paulina Lau
MNMajid Nikpay
Majid Nikpay
ADAnh-Thu Dang
Anh-Thu Dang
RMRuth McPherson
Ruth McPherson
Background: Fibronectin ( FN1 ) is an essential regulator of homodynamic processes and tissue remodeling that have been proposed to contribute to atherosclerosis. Moreover, recent large-scale genome-wide association studies (GWAS) have linked common genetic variants within the FN1 gene to coronary artery disease risk. Methods: Public databases were analyzed by 2-Sample Mendelian Randomization. Expression constructs encoding short FN1 reporter constructs and full-length plasma FN1 variants were introduced in various cell models. Secreted and cellular levels were then analyzed and quantified by SDS-PAGE and fluorescence microscopy. Mass spectrometry and glycosylation analyses were performed to probe possible posttranscriptional differences. Results: Bioinformatic analyses revealed that common coronary artery disease risk single nucleotide polymorphisms in the FN1 locus associate with circulating levels of FN1 and that higher FN1 (fibronectin 1) protein levels in plasma are linked to lower coronary artery disease risk. The coronary artery disease-associated FN1 locus encompasses a common polymorphism that translates a L15Q variant situated within the FN1 signal peptide. Introduction of FN1 reporter constructs, differing at position 15, revealed differences in secretion, with the FN1 Q15 variant being less well secreted. Moreover, the L15Q polymorphism was found to alter glycosylation in some cell models but not in human plasma. Conclusions: In addition to providing novel functional evidence implicating FN1 in cardioprotection, these findings demonstrate that a common variant within a secretion signal peptide regulates protein function.

29 March 2022 in Atherosclerosis
Verified
Journal Article
Closed access
ADAnh-Thu Dang
Anh-Thu Dang
ATAdam W. Turner
Adam W. Turner
PLPaulina Lau
Paulina Lau
DMDhanuddara Mohottalage
Dhanuddara Mohottalage
YFYuet Kay Stephanie Fong
Yuet Kay Stephanie Fong
RMRuth McPherson
Ruth McPherson

1 December 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
SSSebastien Soubeyrand
Sebastien Soubeyrand
PLPaulina Lau
Paulina Lau
MNMajid Nikpay
Majid Nikpay
LMLijiang Ma
Lijiang Ma
JBJohan L.M. Bjorkegren
Johan L.M. Bjorkegren
RMRuth McPherson
Ruth McPherson
BACKGROUND: Genome-wide association studies identified a 20-Kb region of chromosome 8 (8q24.13) associated with plasma lipids, hepatic steatosis, and risk for coronary artery disease. The region is proximal to TRIB1 , and given its well-established role in lipid regulation in animal models, TRIB1 has been proposed to mediate the contribution of the 8q24.13 locus to these traits. This region overlaps a gene encoding the primate-specific long noncoding RNA transcript TRIBAL / TRIB1AL ( TRIB1 -associated locus), but the contribution of TRIBAL to coronary artery disease risk remains untested. METHODS: Using recently available expression quantitative trait loci data and hepatocyte models, we further investigated this locus by Mendelian randomization analysis. Following antisense oligonucleotide targeting of TRIBAL, transcription array, quantitative reverse transcription polymerase chain reaction, and enrichment analyses were performed and effects on apoB and triglyceride secretion were determined. RESULTS: Mendelian randomization analysis supports a causal relationship between genetically determined hepatic TRIBAL expression and markers of hepatic steatosis and coronary artery disease risk. By contrast, expression data sets did not support expression quantitative trait loci relationships between coronary artery disease–associated variants and TRIB1 . TRIBAL suppression reduced the expression of key regulators of triglyceride metabolism and bile acid synthesis. Enrichment analyses identified patterns consistent with impaired metabolic functions, including reduced triglyceride and cholesterol handling ability. Furthermore, TRIBAL suppression was associated with reduced hepatocyte secretion of triglycerides. CONCLUSIONS: This work identifies TRIBAL as a gene bridging the genotype-phenotype relationship at the 8q24.13 locus with effects on genes regulating hepatocyte lipid metabolism and triglyceride secretion.

1 July 2020 in Atherosclerosis
Verified
Journal Article
Closed access
PLPaulina Lau
Paulina Lau
SSSebastien Soubeyrand
Sebastien Soubeyrand
RHRobert Hegele
Robert Hegele
TLThomas A. Lagace
Thomas A. Lagace
RMRuth McPherson
Ruth McPherson